U.S. markets open in 5 hours 49 minutes

Aptose Biosciences Inc. Registe (LTIA.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
4.8400-0.1200 (-2.42%)
As of 9:14AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.9600
Open4.8400
Bid4.9000 x N/A
Ask5.0500 x N/A
Day's Range4.8400 - 4.8400
52 Week Range1.6000 - 8.4000
Volume0
Avg. Volume62
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

      SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit: * Oppenheimer Fall Healthcare Life Sciences & Medtech Summit Date:Tuesday, September 22, 2020  Time:1:40 PM EDT  Format:Fireside Chat (with Matthew Biegler, Senior Analyst, Oppenheimer & Co.)  Webcast:Link The audio webcast can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live events. About AptoseAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.comFor further information, please contact:Aptose Biosciences Inc.LifeSci Advisors, LLC Greg ChowDan Ferry, Managing Director Executive Vice President, CFO617-535-7746 650-718-5028Daniel@LifeSciAdvisors.com gchow@aptose.com     SMP Communications  Susan Pietropaolo  201-923-2049  susan@smpcommunications.com

    • GlobeNewswire

      Aptose to Present at September Investor Conferences

      SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020: * H. C. Wainwright 22nd Annual Global Investment ConferenceDate:Monday, September 14, 2020 Time:2:30 PM EDT Format:Virtual - Presentation Webcast:Link * Cantor Virtual Global Healthcare Conference Date:Thursday, September 17, 2020 Time:10:00 AM EDT Format:Virtual – Fireside Chat Webcast:Link The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live events.About AptoseAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.comFor further information, please contact:Aptose Biosciences Inc.                                               Greg Chow                                                                    Executive Vice President, CFO                                      650-718-5028                                                                 gchow@aptose.com SMP Communications Susan Pietropaolo 201-923-2049 susan@smpcommunications.comLifeSci Advisors, LLC Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com

    • RBC: These 2 Stocks Are Poised to Surge by at Least 80%
      TipRanks

      RBC: These 2 Stocks Are Poised to Surge by at Least 80%

      Breaking record after record, the stock market is on a roll. Hovering at all-time highs, the steady decline of new COVID-19 cases in the U.S. and vaccine hopes have kept the S&P 500’s remarkable rally alive. That said, these movements have spurred unprecedented disparities in sentiment, with some market watchers overwhelmingly bullish while others are unwaveringly bearish.So, how are investors supposed to decide which side to take? The Wall Street pros can lend a hand here. Analysts offer up extensive experience as well as cover stocks you might not otherwise hear of. Seeking out some of the best in the business, we turned to the analysts at RBC Capital, which nabs the third spot on TipRanks’ list of Top Performing Research Firms.The pros from RBC are bullish on two stocks in particular, noting that each could gain at least 80% in the next year. After running the names through TipRanks’ database, we found out that the broader analyst community is also in favor of them, as both sport “Strong Buy” consensus ratings.Xeris Pharmaceuticals Inc. (XERS)Bringing cutting-edge technology to the table, Xeris Pharmaceuticals addresses the issues that arise from water-based delivery systems. With a $3.88 share price, RBC believes XERS' price tag could present investors with an attractive entry point.Representing the firm, analyst Randall Stanicky tells clients that company's glucagon injection Gvoke roughly doubled its market share from Q1 to Q2, and the Gvoke HypoPen (autoinjector), which was launched in July, has “accelerated that growth.” Digging a little deeper, he conducted a survey of 32 physicians to gauge glucagon prescribing patterns and competitive dynamics, and was impressed with the results.According to Stanicky, there are two primary growth levers for Gvoke. “The first is market share capture from legacy glucagon rescue kits, which held 78% TR x share in Q2. In one year’s time, physicians expect Gvoke to comprise 46% of their total glucagon TRx (higher than Eli Lilly’s BAQSIMI, but likely some survey bias), with particular enthusiasm among primary care physicians (PCPs),” he explained. To this end, the analyst expects the product to control 20% of the glucagon market in 2021.As for the second, Stanicky highlights the fact that the overall glucagon market is expanding. “Per our survey, only 67% of Type 1 diabetics and 47% of Type 2 diabetics who should ‘ideally’ be prescribed glucagon actually receive it. This disconnect likely explains why 72% of physicians expect overall glucagon TRx to increase by more than 20% over the next 12 months (our model implies a 26% increase in 2021),” he commented.Wrapping it all up, Stanicky stated, “Overall, our survey suggests that Gvoke has plenty of room to run, with multiple tailwinds that should sustain growth in 2H2020 and beyond. We continue to like the set-up here on our expectation of continued robust uptake.”To this end, Stanicky rates XERS an Outperform (i.e. Buy) along with a $14 price target. Should his thesis play out, a potential twelve-month gain of 263% could be in the cards. (To watch Stanicky’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 5, in fact, have been issued in the last three months. Therefore, the message is clear: XERS is a Strong Buy. Given the $11.60 average price target, shares could skyrocket 201% in the next year. (See XERS stock analysis on TipRanks)Aptose Biosciences (APTO)Developing innovative targeted agents, Aptose Biosciences wants to meet the needs of patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other hematologic malignancies. As it boasts several promising programs progressing through development and a solid cash position, RBC thinks that now is the time to go in on this name.Firm analyst Gregory Renza calls APTO’s clinical advancement of CG-806, its oral reversible kinase inhibitor, “thoughtful,” with it continuing to take steps forward in the development process. Based on a recent update, the dose escalation for CG-806’s Phase 1 B-cell trial has made substantial progress. The intermediate 600mg BID dose has been completed and cleared for safety, with the candidate showing “BTK inhibition and lymphocytosis induction in these CLL patients as well as a clean and well-tolerated profile.”Now, APTO will perform the screening and dosing of the next 750mg BID cohort, which could pave the way for a more detailed update that includes efficacy data at the end of the year. This was confirmed as a company event around virtual ASH2020 in December. Renza also believes this could be a “set-up for potential response data – which will be critical to assessing the profile and ultimate clinical competitiveness of CG-806.”It should be noted that the FDA recently agreed to allow for an AML Phase 1a/b study and possibly a therapeutically active 450mg starting dose, which puts CG-806 on “an accelerated path for dose escalation, activating the likelihood of response in this advanced population,” in Renza’s opinion. Dosing is slated for Q3, with a potentially “rapid path for data intact and aligning to year-end.”To sum it all up, Renza explained, “With a newly bolstered cash position, cohort advancement in CLL, and a newly opened opportunity in AML – all underscored by a palpable company confidence in strategy and execution – we continue to see high opportunity in CG-806 and the set-up both into the second half and beyond helped by a meaningful set of program catalysts.”Given everything APTO has going for it, Renza rates the stock an Outperform (i.e. Buy) rating, along with a $9 price target. This suggests that shares could climb 87% higher in the next year. (To watch Renza’s track record, click here)All in all, other analysts echo Renza’s sentiment. 7 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $10.57, the upside potential comes in at 109%. (See APTO stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.This article was originally posted on TipRanks.